NCT06592456View on ClinicalTrials.gov

A Phase III Clinical Trial Assessing the Immunogenicity and Safety of Lyophilized Live-Attenuated Varicella Vaccine in Healthy Subjects Aged 13 to 55 Years

PHASE3CompletedINTERVENTIONAL
Enrollment

1,200

Participants

Timeline

Start Date

July 21, 2019

Primary Completion Date

October 7, 2021

Study Completion Date

November 8, 2021

Conditions
Chickenpox Vaccines
Interventions
BIOLOGICAL

Chickenpox Vaccines

The vaccines require reconstitution with the provided sterile water for injection nd should be shaken well before use. Each human dose (0.5 ml) contains at least 3.3 log PFU of VZV.

Trial Locations (1)

223399

Huaiyin District Center for Disease Control and prevention, Huaian

All Listed Sponsors
lead

Southeast University, China

OTHER

NCT06592456 - A Phase III Clinical Trial Assessing the Immunogenicity and Safety of Lyophilized Live-Attenuated Varicella Vaccine in Healthy Subjects Aged 13 to 55 Years | Biotech Hunter | Biotech Hunter